We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

44 hedge funds and large institutions have $4.77M invested in VYNE Therapeutics in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

258% more capital invested

Capital invested by funds: $1.33M → $4.77M (+$3.44M)

200% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 4

57% more repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 7

22% more funds holding

Funds holding: 36 → 44 (+8)

9.12% more ownership

Funds ownership: 15.61% → 24.73% (+9.1%)

Holders
44
Holders Change
+8
Holders Change %
+22.22%
% of All Funds
0.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
11
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
AFM
Anson Funds Management
Texas
+$512K
2
SC
Shay Capital
New York
+$454K
3
NCM
Nantahala Capital Management
Connecticut
+$401K
4
ACM
ADAR1 Capital Management
Texas
+$102K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$77.1K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$285K
2
ACA
Acorn Capital Advisors
New York
-$235K
3
Jane Street
Jane Street
New York
-$30K
4
BCM
Bridgeway Capital Management
Texas
-$25.8K
5
CCM
Corsair Capital Management
New York
-$16.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
Commonwealth Equity Services
26
Commonwealth Equity Services
Massachusetts
$10.6K – – –
State Street
27
State Street
Massachusetts
$9.14K – – –
HIS
28
Harvest Investment Services
Illinois
$6.42K – – –
TRCT
29
Tower Research Capital (TRC)
New York
$2.07K -$12 -30 -0.8%
Royal Bank of Canada
30
Royal Bank of Canada
Ontario, Canada
$1K – +1 +0%
Bank of America
31
Bank of America
North Carolina
$973 +$58 +145 +9%
ACA
32
Acorn Capital Advisors
New York
$827 -$235K -585,147 -100%
MLA
33
MB, Levis & Associates
Pennsylvania
$604 – – –
Northwestern Mutual Wealth Management
34
Northwestern Mutual Wealth Management
Wisconsin
$464 +$321 +800 New
HC
35
Hurley Capital
New York
$325 +$225 +561 New
JP Morgan Chase
36
JP Morgan Chase
New York
$85 – – –
Wells Fargo
37
Wells Fargo
California
$38 – – –
Morgan Stanley
38
Morgan Stanley
New York
$25 -$348 -868 -95%
TC
39
Truvestments Capital
Florida
$15 – – –
FFA
40
Farther Finance Advisors
California
$9 – – –
NFSG
41
Newbridge Financial Services Group
Florida
$6 – – –
BBA
42
Baker Bros. Advisors
New York
– -$285K -851,353 Closed
BCM
43
Bridgeway Capital Management
Texas
– -$25.8K -76,958 Closed
CCM
44
Corsair Capital Management
New York
– -$16.8K -50,000 Closed
FFO
45
Fortitude Family Office
Arizona
– -$228 -680 Closed
1
2

VYNE Hedge Fund Activity: Q4 2025 in Review

44 of the 8,225 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q4 2025, worth a combined $4.77M — up 258% from $1.33M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new VYNE positions and 4 closed out — a net gain of 8 holders — while 11 added to existing stakes and 7 trimmed.

The largest buyer was Anson Funds Management, opening a new position worth an estimated $512K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $285K sold.

  • 44 institutional investors held VYNE Therapeutics (VYNE) as of Q4 2025, up from 36 in Q3 2025.
  • Funds reported $4.77M of VYNE Therapeutics stock for Q4 2025, up 258% quarter-over-quarter.
  • 12 funds opened new VYNE Therapeutics positions in Q4 2025 and 4 closed out, a net change of +8 holders.
  • The largest VYNE Therapeutics buyer in Q4 2025 was Anson Funds Management, an estimated $512K added.
  • The largest VYNE Therapeutics seller in Q4 2025 was Baker Bros. Advisors, an estimated $285K sold.

Based on aggregated 13F filings for Q4 2025.